Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > News > Tuberculosis study reveals possible new target to reduce disease susceptibility

Tuberculosis study reveals possible new target to reduce disease susceptibility

Date time 21 February, 2018

Tuberculosis study reveals possible new target to reduce disease susceptibility.

Australians are fortunate to now largely be protected from Tuberculosis (TB), but this means many are unaware of the existing global burden of this deadly disease. One fourth of the world’s population is infected with TB, a disease which is difficult to treat due to drug resistance. A collaborative study has revealed a possible new target to treat TB. The research has been published in Nature Communications.

Scientists led by Centenary Institute’s Dr Warwick Britton and Dr Carl Feng at the University of Sydney, found that a genetic variation called a single-nucleotide polymorphism, found in the human gene called the IFNAR1, is associated with decreased susceptibility to tuberculosis and an increased risk of viral hepatitis in Chinese populations- the study revealing the detrimental effect of IFN signalling in tuberculosis susceptibility.

The world Health Organisation has recognised TB as a significant global issue. Vowing to work towards eradication of the disease by 2030. This study could be a significant step towards that ambitious goal. This new information could be beneficial to help scientists and doctors target IFN signalling in humans to reduce TB susceptibility.

The work was a collaborative project between researchers at Centenary Institute, The Hudson Institute of Medical Research, four Medical Research Hospitals in China, NSW and The University of Sydney.

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Recent Stories

  • Meet Dr Bobby Boumelhem

    Dr Bobby Boumelhem, a dedicated researcher at the Centenary Institute, is on a mission to enhance the quality of life for individuals grappling with liver disease. Diseases such as hepatitis, liver cancer, non-alcoholic fatty liver disease and cirrhosis pose significant health challenges.
    News Type: Profiles
    Date 22 Sep 2023
  • Cancer drug for COVID-19

    Researchers, including Dr Matt Johansen from the Centenary UTS Centre for Inflammation and Professor Phil Hansbro, Director of the Centenary UTS Centre for Inflammation, have discovered that a cancer drug could play an important role in limiting the damaging effects of lung disease in COVID-19 patients.
    News Type: Research News
    Date 19 Sep 2023
  • Centenary Institute supports the Voice

    As a medical research institute deeply committed to improving the health outcomes of all Australians, the Centenary Institute wholeheartedly endorses the principles of voice, treaty, and truth, and gives its full support to the Voice to Parliament.
    News Type: Institute
    Date 11 Sep 2023
  • Link between gut bacteria and long-term COVID-19 effects revealed

    Researchers, including from the Centenary Institute, have highlighted a potential link between gut microbiota (the collection of bacteria residing in the digestive system) and enduring health problems experienced by individuals who have recovered from COVID-19.
    News Type: Research News
    Date 07 Sep 2023

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram